Navigation Links
Cerecor Announces Clearance of IND for FP01
Date:4/11/2012

BALTIMORE, April 11, 2012 /PRNewswire/ -- Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, today announced that its Investigational New Drug (IND) Application for FP01 for the treatment of cough has cleared the 30 day deliberation period by the U.S. Food and Drug Administration (FDA).  The Company plans to immediately characterize the pharmacokinetics of FP01 lozenges in humans and thereafter to initiate an exploratory Phase II acute cough study in healthy subjects with upper respiratory tract infections (URTI). 

(Logo: http://photos.prnewswire.com/prnh/20120411/PH85852LOGO )

"Acceptance by the FDA of this application and the advancement of FP01 to clinical testing are important milestones for the Company and key steps along the path to commercialize a treatment for acute and chronic cough. The data we plan to generate from the initial Phase II study will educate us about the effect size of FP01 as an antitussive, providing for future studies," said Dr. Blake Paterson, CEO and co-founder of Cerecor.

About Cerecor Inc.

Cerecor Inc. ("Cerecor" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. Cerecor's product pipeline also includes preclinical drug development candidates in cognition and schizophreniawww.cerecor.com

For More Information, contact:
John Dierkes
Kennedy Advisors
john@kennedyadvice.com
(410) 935-9334


'/>"/>
SOURCE Cerecor Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Botanic Announces Results of Annual General Meeting
2. iBio Announces Production of Biosimilar Palivizumab with its iBioLaunch™ Technology
3. SafeWire, LLC. Announces first US product launch of Y-wire™
4. Sunpeaks Ventures Announces Letter of Intent to Export Clotamin to Top Russian Pharmacies
5. Rapid Fire Marketing Announces the First Shipment of its Vapor Inhaler Model Named the CannaCig Has Passed All Patient Tests; Second Round of Production to Start This Week
6. Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores
7. Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2012 Results
8. BioNeutral Group Announces Positive Results for the Ygiene 206 Sterilization Tests
9. Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
10. BONESUPPORTS New CEO Announces 100 Day Plan
11. Sunpeaks Ventures Announces Agreement with Albeck Financial Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
(Date:6/24/2016)... ... , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event ... that have been wounded in battle and their families. Venture Construction Group is a ...
Breaking Medicine News(10 mins):